Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 1/20 | 0.49 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12181730 | 0.88 | MAPT (0.53) | STIM1ORAI1GRM4MAPTTHRB | |
| SCHEMBL15165012 | 0.85 | RAB9A (0.50) | GRM4PKMMAPTSMN1; SMN2CASP3 | |
| SCHEMBL21786604 | 0.83 | ORAI1 (0.60) | STIM1ORAI1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL12156000 | 0.83 | STIM1 (0.53) | STIM1ORAI1GRM4MAPTTHRB | |
| SCHEMBL12155377 | 0.82 | STIM1 (0.48) | STIM1ORAI1SMN1; SMN2CYP2C9 | |
| SCHEMBL22787019 | 0.82 | TMPRSS4 (0.48) | STIM1ORAI1GRM4MAPTSMN1; SMN2 | |
| SCHEMBL2594381 | 0.82 | STIM1 (0.49) | STIM1ORAI1GRM4RXFP1MAPT | |
| SCHEMBL14887485 | 0.81 | CRACR2A (0.49) | STIM1ORAI1MAPTTHRBSMN1; SMN2 | |
| SCHEMBL12155729 | 0.81 | SCN10A (0.49) | STIM1ORAI1SMN1; SMN2 | |
| SCHEMBL28398111 | 0.80 | STIM1 (0.53) | STIM1ORAI1GRM4RXFP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563759-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-2563759-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-9353099-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353099-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150361075-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-17 | — | — | US | disclosed |
| US-20150361075-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-17 | — | — | US | disclosed |
| US-9090612-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090612-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140243366-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243366-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8754219-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754219-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130203818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2563759-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011139765-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139765-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243366-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885GRM4 1253/4885 |
| US-20130203818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885GRM4 1253/4885 |
| US-20150361075-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885GRM4 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.